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Background: Adequate lymph nodes resection in rectal cancer is important for staging and local control. This
retrospective analysis single center study evaluated the effect of neoadjuvant chemoradiation on the number of
lymph nodes in rectal carcinoma, considering some clinicopathological parameters.
Methods: A total of 111 patients undergone total mesorectal excision for rectal adenocarcinoma from July 2005 to
May 2012 in our center were included. No patient underwent any prior pelvic surgery or radiotherapy.
Chemoradiotherapy was indicated in patients with rectal cancer stage II or III before chemoradiation.
Results: One-hundred and eleven patients were considered. The mean age was 67.6 yrs (range 36 – 84, SD 10.8).
Fifty (45.0%) received neoadjuvant therapy before resection. The mean number of removed lymph nodes was 13.6
(range 0–39, SD 7.3). In the patients who received neoadjuvant therapy the number of nodes detected was lower
(11.5, SD 6.5 vs. 15.3, SD 7.5, p = 0.006). 37.4% of patients with preoperative chemoradiotherapy had 12 or more
lymph nodes in the specimen compared to the 63.6% of those who had surgery at the first step (p: 0.006).
Other factors associated in univariate analysis with lower lymph nodes yield included stage (p 0.005) and grade
(p 0.0003) of the tumour. Age, sex, tumor site, type of operation, surgeons and pathologists did not weight upon
the number of the removed lymph nodes.
Conclusion: In TME surgery for rectal cancer, preoperative CRT results into a reduction of lymph nodes yield in
univariate analisys and linear regression.
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The gold standard for rectal cancer is the total mesorec-
tal excision (TME) who allow adequate resection of the
tumour and the regional lymph nodes. The International
Union Against Cancer (UICC) and the American Joint
Committee on Cancer (AJCC) decided to recommend a
minimum of 12 lymph nodes for an adequate staging of
colorectal cancer [1] in accordance with the guideline of
the World Congress of Gastroenterology of 1990 [2]. An
accurate nodal status is essential because there is a
significant correlation between the number of nodes* Correspondence: stefanoscabini@libero.it
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reproduction in any medium, provided the orretrieved and survival of patients. The risk of understa-
ging is that some patients, who would benefit from adju-
vant therapy, would not be offered any [1]. Besides, a
lower number of lymph nodes removed is associated
with a poorer survival and, especially in rectal cancer,
with a higher rates of local recurrence [3-6].
Preoperative radiotherapy decrease the number of
lymph nodes yield in surgical specimen [7-10]. Many
factors are associated to reduction of number of nodes
after chemoradiotherapy: the immune response and fi-
brosis in lymph nodes exposed to radiotherapy, which re-
sults in a difficult identification of nodes in the specimen.
This study aims to observe the effect of preoperative
chemoradiotherapy (CRT) on the number of lymph
nodes retrieved in the specimen in patients undergoing
a TME for rectal cancer.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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We observed retrospectively all the patients who had
TME for rectal cancer at a single institution from July
2005 to May 2012; 111 cases are enrolled and satisfied
the inclusion criteria (middle or low rectal cancer, no
previous pelvic surgery or radiotherapy, R0-surgery, no
conversion from laparoscopy to laparotomy). The op-
erations performed by one of five surgeons who had
experience in colorectal surgery (more than 20 colo-
rectal resection/year). All the patients had TME surgi-
cal approach.
All the patients had preoperative staging with chest
and abdomen CT scans, pelvic MRI and endorectal
ultrasound. Patients with stage I disease or who rejected
neoadjuvant therapy had primary surgery, patients with
Stage IV disease were excluded from the study. Patients
with stage II or III disease received neoadjuvant CRT
(45 Gy in 25 fractions over a 5-week period with a com-
bination of capecitabine 825 mg bid uninterrupted for
42 days). Eight weeks after finishing the CRT, the pa-
tients underwent surgery after restaging by MRI study
and endorectal ultrasound. The type of surgery depended
on the level of the tumour. We performed a TME proced-
ure with Miles’ operation if was not possible to preserve
the sphincter; otherwise, low anterior resection (LAR) was
done. High-ligation of the inferior mesenteric artery was
routinely, except in "dolichosigma" with the possibility to
perform a tension-free anastomosis. All resection speci-
men were examined by 3 dedicated pathologists according
to a standardized histopatologic protocol with evaluation
of pTNM category including the total number of resected
nodes and the number of positive nodes. All lymph nodes
present must be examined histologically; nodal examin-
ation must not stop once 12 nodes have been identified. If
less than 12 lymph nodes are found, consideration should
be given to placing the fat into a lymph node highlighting
solution [11]. Histopathologic tumor regression after neo-
adjuvant radiochemotherapy was classified according to
Dvorak score [8].
The study have been performed at Oncologic Surgery
and Implantable Systems Unit, Department of Emer-
gency, IRCCS San Martino IST, Genoa, Italy. The study
obtained the approval of ethics committee of IRCCS San
Martino IST of Genoa (Italy). (protocol number 1/2013).
Excel (Microsoft®) was employed to obtain the patient
records.
Statistical analysis
Correlation between numbers of lymph nodes and clinico-
pathological parameters was evaluated. The association
was tested using the chi-squared test or Mann–Whitney
U test (SPPS 14.0 for Windows, SPPS Inc. Chicago, IL).
Linear regression was performed. The significant level was
set to p < 0.05 for all tests.Results
The clinicopathological parameters are shown in Table 1.
Out of the 111 patients, 63 were men and 48 women
with a mean age of 67.6 yrs (range 36 – 84, SD 10.8).
79.3% of the patients were over 60 years old. All the tu-
mours were adenocarcinoma. 35.1% of the patients with
Table 2 Factors influencing lymph node yield (univariate
analysis)
Parameters Lymph node SD P
Total 13.6 7.3
Age (years): 0.50
<60 (23) 14.5 8.1
>60 (88) 13.3 7.1
Sex: 0.79
Male (63) 13.7 7.1
Female (48) 13.4 7.6
Tumor site: 0.24
Middle (45) 14.6 7.6
Lower (66) 12.9 7.1
Tumor grade: 0.0003
G1 (5) 13.2 6.8
G2 (76) 14.1 7.3
G3 (10) 19.7 7.0
Gx (20) 8.4 3.7
Stage: 0.005
0 (7) 11.7 5.4
I (31) 12 6.4
II (22) 15.5 8.3
III (39) 15.8 7.3
X (12) 7.9 4.5
Type of surgery: 0.65
Low anterior resection (76) 13.4 7.0
Abdominalperineal resection (35) 14.0 7.08
Surgical approach: 0.02
Open (38) 15.8 8.3
Laparoscopy (73) 12.4 6.4
Neoadjuvant: 0.006
No (61) 15.3 7.7
Yes (50) 11.5 6.5
Surgeons: 0.18
1 (23) 16.3 10.3
2 (16) 13.6 7.3
3 (26) 14.0 5.3
4 (18) 13 6.7
5 (28) 11.3 5.8
Pathologists: 0.20
1 (60) 12.9 6.2
2 (31) 14.0 7.6
3 (10) 10.6 5.6
4 (10) 16.8 8.1
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Stage I 27.9%, a Stage II 19.8%, a Stage III 35.2%; the pa-
tients with a unknown pT stage after neoadjuvant ther-
apy was 10.8%. Most tumours were in the lower rectum
(59.5%). Sphincter sparing surgery was performed in
68.5% of the patients, APR in 31.5%. Fifty patients
(45.0%) had neoadjuvant CRT. The mean time elapsed
between the completion of the CRT and the surgery was
8.8 weeks (SD: +/− 1.45).
The mean number of lymph nodes in this series of pa-
tients was 13.6 (SD: 7.3). The patients who received pre-
operative CRT presented a lower number of retrieved
lymph nodes than patients who received surgery without
neoadjuvant therapy (11.5, SD 6.5 vs. 15.3, SD 7.5,
p = 0.006) (Table 2). 37.4% of patients who received
neoadjuvant therapy had 12 or more removed lymph
nodes, while 63.6% of patients not undergone a preopera-
tive therapy had 12 or more nodes yield (p 0.05).
Other factors associated with a lower yield of lymph
nodes was tumour grade, tumour staging and surgical
approach. Regression of the data showed a significant as-
sociation with only CRT (Table 3). Patient age, gender,
tumour site, type of surgery, surgeons and pathologists
had no impact on lymph node yield.
Discussion
In colorectal cancer, an appropriate dissection of mesen-
teric lymph nodes provides an adequate staging of the
tumour [1], which improves the evaluation of manage-
ment and prognosis of the disease [3,4,6]. Furthermore,
the number of lymph nodes removed during surgery is
directly proportional to the probability of detecting dis-
ease in them [12]. On the other hand, an adequate resec-
tion of lymph nodes decreases the incidence of local
recurrences [13,14] and improves the patient survival
[15-17]. So far, it’s still missing a clear guide about the
appropriate number of lymph nodes to be removed in
rectal cancer.
In the literature, from single case series a 7 to 20 range
has been proposed [6,18-21]. In 1990, the World Congress
of Gastroenterology in Sydney supported a minimum of
12 lymph nodes shall be excised for assessment [2]. Simi-
lar numbers are endorsed by the NCI issued guidelines
[1]. Quoting from the last edition of TNM classification of
the American Joint Committee on Cancer, “It is important
to obtain least 10 to 14 lymph nodes in radical colon
and rectum resections in patients without neoadjuvant
therapy [22].
The presence of both colon and rectal cancers in the
same disease represents another important limitation of
these guidelines.
To overcome this issue, in the present study we only
investigate patients suffering from rectal cancer and be-
ing treated with a laparoscopic TME. The mean number
Table 3 Factors influencing therapy and lymph node
yield (linear regression)
Variable Lymph nodes SD P value
Total 13.6 7.3
Tumor grade: 0.08
G1 (5) 13.2 6.8
G2 (76) 14.1 7.3
G3 (10) 19.7 7.0
Gx (20) 8.4 3.7
Stage: 0.46
0 (7) 11.7 5.4
I (31) 12 6.4
II (22) 15.5 8.3
III (39) 15.8 7.3
X (12) 7.9 4.5
Surgical approach: 0.19
Open (38) 15.8 8.3
Laparoscopy (73) 12.4 6.4
Neoadjuvant: 0.05
No (61) 15.3 7.7
Yes (50) 11.5 6.5
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firms results obtained in previous studies, showing that
the average varies between 5 and 16 lymph nodes
[8,10,15,16,23-27]. The variety of these numbers is due
to different factors. First of all, it is related to the sur-
geon’s ability in performing an adequate TME. Then, the
pathologist’s accuracy is fundamental for detecting meta-
static lymph nodes [28,29]. The third factor influencing
these numbers might be related to physical and ana-
tomic differences of the patients.
The aim of our study is to evaluate the effect of che-
motherapy and radiotherapy combination. The Dutch
Colorectal Cancer Group, which randomly subdivides
the patients to receive preoperative short radiotherapy
course followed by TME surgery or TME surgery only,
found out that there was a significant difference in the
number of retrieved lymph nodes [9].
On average, we retrieved 7.7 lymph nodes from pa-
tients undergoing preoperative radiotherapy and 9.7
lymph nodes in surgery-only patients. Other studies
on preoperative radiotherapy reached similar conclu-
sions [8,10]. Wichmann and co-workers compared pa-
tients who had primary surgery and those who had
CRT before surgery, and reported a significant difference
in the number of excised lymph nodes between the two
groups (19.1 for surgery vs. 13.6 for preoperative therapy,
p = <0.05) 30. Another study obtained the same result
(17 vs. 13, respectively) [27].We observed a significant difference between the num-
bers of retrieved lymph nodes in both groups (11.6 vs.
15.6, p = 0.03). Hence, we can affirm that radiotherapy
was associated with the reduction of lymph node surgical
retrieval. The effect of single chemotherapy strategy is less
clear. Sermier and co-workers observed that the impact of
preoperative radiotherapy on yielding lymph nodes is
time-dependent [26]. However, the authors observed that
for 5 patients subjected to APR for recurrent anal cancer
more than 5 months after the end of the radiotherapy
the regression analysis was way different. In our co-
hort of patients, surgery was always performed after
8.8 weeks (SD: +/− 1.45) weeks from the end of the
neoadjuvant therapy.
Age, sex and level of the tumour (mid or lower) do
not significantly influence lymph node yield. This is par-
tially in contrast with other studies where it is shown an
higher lymph node yield in younger patients [8,23,24],
and tumour mid rectal level [25]. Conversely, results
from our cohort confirmed the lack of association be-
tween number of lymph nodes and male sex [8,23,25].
Also, the type of surgery (APR vs. LAR) and the surgeon
and pathologist’s experience have been shown not to in-
fluence the lymph node yield. These data indicated that
the codification of procedures between surgeons and
pathologists might be strongly recommended for gua-
rantee a standard high quality of management of co-
lorectal cancer [27,30-33]. In the present study we
considered also surgical approach (laparotomic or lap-
aroscopic TME). All the 5 surgeons who participated at
the operations were devoted to colorectal surgery and
were not associated with a different number of retrieved
lymph nodes. A less number of nodes retrieved in speci-
men of rectal cancer underwent at laparoscopic TME is
the result of greater number of neoadjuvant therapy in
this group of patients (high grade of difference between
two groups - p: 0.0009-). We analyzed also the role of
pathologists. In our center, where the mean number of
colorectal resection is 120/year, surgeons and patholo-
gists are specialized in the treatment of this illness, thus
their role in the lymphadenectomy is codified and are
not associated with a different number of retrieved
nodes. In our opinion and in other studies [27] this is
important to improve the quality of colorectal resection
for cancer.
Finally, the pathological T stage and grade were shown
to be predictive factors for the number of lymph nodes
removed during surgery. These results were partially con-
firmed in previous studies [8,10,23,25,27]. However, the
sample size is limited, the groups are heterogeneous at
baseline and this aspect was not considered in univariate
and multivariate analysis.
In conclusion, preoperative CRT a smaller lymph node
yield is obtained after neoadjuvant CRT upon rectal
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of the tumour, need to be taken into account when con-
sidering the surgical lymph node yield. All these factors
must be collectively considered in the assessment of
lymph node resection adequacy in rectal carcinoma. How-
ever, in our experience, the only factor associated
with reducing of nodes retrieved in the specimen was
the neoadjuvant therapy.
Is this the future of a correct staging of rectal cancer?
The lymphadenectomy is at present an integral part of
rectal surgery and surgeons must perform it correctly to
improve their results. However, in rectal cancer surgeons
pay duty to radiotherapy, although absolutely necessary
when indicated, in the dissection. Nevertheless for the
future probably another “staging system” will be neces-
sary, in order to take into account also biologic aspects
of the tumour [34-39]. This would allow identifying pa-
tients with aggressive illness and treating them with
more effective and less toxic therapies, although at the
moment consensus has yet to be reached with regard to
indications for adjuvant chemotherapy following neo-
adjuvant chemoradiation for rectal cancer [38,40].
Conclusions
Preoperative CRT is associated with a reduction in the
yield of lymph nodes in rectal cancer surgery. Other fac-
tors, such as stage and grade of the tumour, may also
affect lymph node yield. All these factors should be taken
into account when evaluating the adequacy of lymph node
resection in rectal carcinoma.
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